Xylazine in Overdose Deaths and Forensic Drug Reports in US States, 2019-2022

Manuel Cano,Raminta Daniulaityte,Flavio Marsiglia

DOI: https://doi.org/10.1001/jamanetworkopen.2023.50630

2024-01-07

JAMA Network Open

Abstract:This cross-sectional study of drug overdose deaths in the US examines trends in xylazine-related overdoses and the prevalence of including xylazine in state-level forensic reports.

medicine, general & internal

What problem does this paper attempt to address?

Drug Overdose Deaths Involving Xylazine, United States, 2018–2021

Merianne Spencer,Jodi Cisewski,Margaret Warner,Matthew Garnett

DOI: https://doi.org/10.15620/cdc:129519

2023-06-30

Abstract:This study presents trends in drug overdose death rates involving xylazine from 2018 through 2021, overall and by sex. Rates of drug overdose deaths involving xylazine are also presented by age group and race and Hispanic origin from 2020 to 2021, and by the U.S. Department of Health and Human Services public health regions in 2021. Co-involvement for the most frequent drugs involved with xylazine is also reported.
Public health impact and harm reduction implications of xylazine-involved overdoses: a narrative review

David T. Zhu

DOI: https://doi.org/10.1186/s12954-023-00867-x

2023-09-14

Harm Reduction Journal

Abstract:Xylazine, an α2-adrenoceptor agonist sedative commonly used in veterinary medicine, is not approved for human use. Nevertheless, xylazine-involved overdose rates have surged in recent years, fueled by an increasingly toxic and synthetic illicit drug supply in North America.

substance abuse
Xylazine Spreads Across the US: A Growing Component of the Increasingly Synthetic and Polysubstance Overdose Crisis

Joseph Friedman,Fernando Montero Castillo,Phillippe Bourgois,Rafik Wahbi,Daniel Dye,David Goodman,Chelsea Shover

DOI: https://doi.org/10.1101/2021.09.20.21263680

2021-09-26

Abstract:Background Recent sharp exacerbations of the US overdose crisis have been linked to systemic polysubstance use and potent synthetic compounds in numerous drug classes. Xylazine is a veterinary tranquilizer, long noted in the opioid supply of Puerto Rico, and more recently Philadelphia. Yet its national growth over time, geographic distribution, and potential role in the shifting US overdose risk environment are poorly characterized. Methods In this sequential mixed methods study, xylazine was increasingly observed by our ethnographic team over many years of intensive participant observation fieldwork in Philadelphia among drug sellers and people who inject drugs (PWID). Subsequently, we systematically searched for records describing xylazine-involved overdose mortality across the US and assessed time trends and overlap with other drugs. Results In 10 jurisdictions—representing all 4 US Census Regions—xylazine was found to be increasingly implicated in overdose mortality, rising from 0.36% of deaths in 2015 to 6.7% in 2020. The highest xylazine prevalence in the recent data was observed in Philadelphia, (25.8% of deaths), followed by Maryland (19.3%) and Connecticut (10.2%). Illicitly-manufactured-fentanyls were present in 98.4% of xylazine-involved-overdose-deaths— suggesting a strong ecological link—as well as cocaine (45.4%), benzodiazepines (28.4%), heroin (23.3%), and alcohol (19.7%). PWID in Philadelphia described xylazine as a sought-after adulterant that improves euphoria and lengthens the short duration of fentanyl injections, in particular. They also linked it to increased risk of soft tissue infection and overdose. Conclusions We summarize evidence that xylazine is increasingly implicated in overdose deaths across the US and is linked to the proliferation of illicitly-manufactured-fentanyls. We document hypothesis-generating ethnographic accounts linking it to health risks for PWID. Nevertheless, many jurisdictions do not routinely test for xylazine, and it is not tracked in federal overdose statistics. Further efforts are needed to provide PWID with services that can help to minimize additional risks associated with a shifting drug supply.
Xylazine in the Unregulated Drug Market: An Integrative Review of Its Prevalence, Health Impacts, and Detection and Intervention Challenges in the United States

Evans F Kyei,Grace K Kyei,Rockson Ansong,Charles K Boakye,Ernest Asamoah

DOI: https://doi.org/10.1177/15271544241268386

Abstract:Xylazine, a veterinary sedative, has emerged as a concerning element in the landscape of substance use in the United States. This integrative review synthesizes evidence from a systematic examination of 14 selected studies conducted between 2008 and 2023. The primary objective is to comprehensively understand the epidemiology and prevalence of xylazine use, particularly its involvement in drug-related deaths, regional variations, national impact, co-occurrence with opioids, and challenges associated with detection and intervention. The results underscore stark regional disparities in xylazine prevalence. West Virginia and Miami-Dade County have experienced alarming surges in xylazine-involved drug-related deaths. Nationally, its influence extends beyond regional boundaries, predominantly affecting white males in the Northeast. The co-occurrence of xylazine with opioids, especially fentanyl and heroin, significantly amplifies the risks of fatal overdoses. Detecting xylazine presents formidable challenges due to its frequent presence alongside other substances, necessitating enhanced surveillance and more effective detection methods. User perspectives emerge as pivotal, emphasizing the importance of user-informed harm reduction strategies. In conclusion, this review has significant policy implications. Tailored, region-specific strategies are imperative to address the diverse prevalence of xylazine use. A nationwide response is indispensable, prioritizing harm reduction initiatives, enhanced detection methods, and active user engagement. The multifaceted nature of the xylazine issue requires comprehensive approaches to mitigate its profound risks effectively. Policymakers are urged to consider regional disparities and the co-occurrence of xylazine with opioids when crafting targeted interventions. Immediate, user-informed harm reduction is vital to address the evolving landscape of xylazine use in the United States.
Xylazine Abuse, The Growing Risk: A Review of Its Effects, Upsurge Use and Associated Fatalities in the USA and Puerto Rico.

Luz A. Silva-Torres,Ashraf Mozayani

DOI: https://doi.org/10.1016/j.jflm.2024.102780

IF: 1.691

2024-10-21

Journal of Forensic and Legal Medicine

Abstract:In the last decade, the opioid overdose epidemic has been exacerbated by the emerging drug of abuse, xylazine. This veterinary anesthetic, an alpha-2 agonist, not only potentiates the fatal effects of opioids but also causes toxic endothelial effects. This review aims to assess the impact of xylazine use and overdoses within the context of the opioid crisis as a public health issue. The research used data from scientific publications, state health reports, and analyses from the Institute of Forensic Sciences of Puerto Rico. The databases PubMed, Google Scholar, and Scopus were searched for relevant publications. The search strategy employed two groups of terms: the drug of interest (xylazine) and types of exposure (drug use, overdose, substance abuse, etc.). The initial search in PubMed was then extrapolated, and the search terms were adjusted for appropriate database syntax. According to the most recent publications and CDC data in the USA, approximately 95% of fentanyl overdose cases involve xylazine, while the other 5% of overdose cases are attributed solely to xylazine, predominantly administered intravenously. In the last four years, more than 4,000 overdose deaths have been related to xylazine use; the northeastern United States had reported the most significant number of deaths. This number changes daily as reanalysis results and new data are published. Less than 50% of states perform tests for xylazine detection or maintain statistical monitoring of overdoses related to this drug. The absence of testing impedes emergency room physicians from making accurate diagnoses, increasing the likelihood of fatal overdoses. This review highlights five major concerns: (1) The recognition of intoxication as a primary concern and the unavailability of alpha-2 antagonists for treatment. (2) The challenges in the clinical setting linked to xylazine abuse and its co-administration with substances like fentanyl and its analogs. (3) The necessity for robust government statistical resources for the unification and dissemination of critical overdose and emerging drug abuse detection information. (4) The need for effective rehabilitation programs, including psychosocial support and treatment interventions, to respond to this public health crisis. (5) The urgency for further research to understand the prevalence, toxic effects of chronic or acute use, and the clinical implications in xylazine users, including the development of alpha-2 antagonists for treatment. We conclude that addressing these concerns is crucial to working with the xylazine abuse situation.

medicine, legal
Opioid overdoses involving xylazine in emergency department patients: a multicenter study

Jennifer S. Love,Michael Levine,Kim Aldy,Jeffrey Brent,Alex J. Krotulski,Barry K. Logan,Carmen Vargas-Torres,Sara E. Walton,Alexandra Amaducci,Diane Calello,Robert Hendrickson,Adrienne Hughes,Anita Kurt,Bryan Judge,Anthony Pizon,Evan Schwarz,Joshua Shulman,Paul Wax,Alex F. Manini,Timothy Wiegan

DOI: https://doi.org/10.1080/15563650.2022.2159427

2023-04-06

Clinical Toxicology

Abstract:Illicit opioids, consisting largely of fentanyl, novel synthetic opioids, and adulterants, are the primary cause of drug overdose fatality in the United States. Xylazine, an alpha-2 adrenergic agonist and veterinary tranquilizer, is being increasingly detected among decedents following illicit opioid overdose. Clinical outcomes in non-fatal overdose involving xylazine are unexplored. Therefore, among emergency department patients with illicit opioid overdose, we evaluated clinical outcome differences for patients with and without xylazine exposures. This multicenter, prospective cohort study enrolled adult patients with opioid overdose who presented to one of nine United States emergency departments between 21 September 2020, and 17 August 2021. Patients with opioid overdose were screened and included if they tested positive for an illicit opioid (heroin, fentanyl, fentanyl analog, or novel synthetic opioid) or xylazine. Patient serum was analyzed via liquid chromatography quadrupole time-of-flight mass spectroscopy to detect current illicit opioids, novel synthetic opioids, xylazine and adulterants. Overdose severity surrogate outcomes were: (a) cardiac arrest requiring cardiopulmonary resuscitation (primary); and (b) coma within 4 h of arrival (secondary). Three hundred and twenty-one patients met inclusion criteria: 90 tested positive for xylazine and 231 were negative. The primary outcome occurred in 37 patients, and the secondary outcome occurred in 111 patients. Using multivariable regression analysis, patients positive for xylazine had significantly lower adjusted odds of cardiac arrest (adjusted OR 0.30, 95% CI 0.10–0.92) and coma (adjusted OR 0.52, 95% CI 0.29–0.94). In this large multicenter cohort, cardiac arrest and coma in emergency department patients with illicit opioid overdose were significantly less severe in those testing positive for xylazine.

toxicology
Illicitly Manufactured Fentanyl–Involved Overdose Deaths with Detected Xylazine — United States, January 2019–June 2022

Mbabazi Kariisa,Julie O’Donnell,Sagar Kumar,Christine L. Mattson,Bruce A. Goldberger

DOI: https://doi.org/10.15585/mmwr.mm7226a4

2023-06-30

Abstract:This report describes increases in illicitly manufactured fentanyl-involved overdose deaths with the nonopioid sedative xylazine detected.

public, environmental & occupational health
Analytical methods for the determination of xylazine in pharmaceutical, clinical and forensic matrices – A review

Sachil Kumar,Hemi Gayakwad,Tulsidas R Baggi

DOI: https://doi.org/10.1177/00258024241275899

2024-08-26

Medicine Science and the Law

Abstract:Medicine, Science and the Law, Ahead of Print. Xylazine, a non-opioid veterinary anaesthetic tranquillizer that is not licensed for human use, has been linked to an increase in overdose fatalities worldwide. The study delves into the forensic aspects of xylazine usage, emphasizing on chemical, clinical and toxicological analyses of drug seizures, bodily fluids and tissues. It advocates for validated analytical methods for determining xylazine. This study provides supporting material to pave the path for the usage and development of relevant and verified alternative screening and confirmation methods for laboratories. Google Scholar, Scopus, Science Direct and PubMed were searched for relevant articles and case reports in relation to xylazine misuse and established analytical methods for forensic investigation until April 2023. A total of 79 articles were evaluated, and 40 publications met the inclusion criteria. The most prevalent xylazine exposures recorded were incidental and intentional misuse/abuse. Common symptoms upon presentation were hypotension, bradycardia, drowsiness and lethargy, although mortality was less prevalent. Solid-phase extraction and liquid–liquid extraction are two extensively used sample preparation techniques. These techniques are used to extract desired analytes from complex matrices. Several analytical techniques have been stated, including GC–MS, LC–MS/MS, HPLC–DAD and others. The analytical procedures used are determined by the matrices involved, the amount of xylazine present, interfering compounds, the degree of precision required and the laboratory infrastructure. In the present context, the LC–MS/MS methods are preferred as the gold standard. In the near future, many analytical techniques such as capillary electrophoresis, PSI-MS, immuno-analytical techniques and SERRS may show significant potential.

law,medicine, legal
Modeling Changes of Fatal Xylazine-Involved Drug Overdoses in Connecticut Across Time

Antoinette V Thuillier,Yong Qiao,Zhao H Wu

DOI: https://doi.org/10.1080/10826084.2024.2393220

Abstract:Background: Fatal drug overdoses have involved both xylazine and fentanyl. Xylazine is a non-opioid substance used in veterinary medicine. This study aimed to model changes in fatal xylazine-involved drug overdose deaths from 2019 to 2023 in Connecticut using overdose death data from the Office of the Chief Medical Examiner. Methods: Xylazine-involved drug overdose fatality rates were calculated by number of deaths per year per 100,000 population from 2019 to 2023. We used joinpoint regression modeling to evaluate quarterly overdose rates across age, number of drugs, and drug types with a significance level of p < 0.05. Results: From 2019 to 2023, there were 1116 xylazine-involved fatal overdoses with a cumulative rate of 31.3 deaths per 100,000. Xylazine-involved overdose death rates were significantly higher in Hispanic populations compared to both non-Hispanic White and Black populations (p < 0.05). The joinpoint analyses showed that xylazine-fentanyl mortality rates significantly increased by 0.18 per 100,000 per quarter from 2019 to 2022. Xylazine-fentanyl overdoses involving at least 4 or 5 substances significantly increased. Windham, Hartford, New London, and New Haven counties had the highest xylazine-involved death rates. Conclusion: Xylazine-fentanyl deaths increased from 2019 to 2023, and often involved multiple substances (e.g., cocaine, ethanol, benzodiazepines, and oxycodone). Results show Hispanic populations, those aged 35-49, and 50+ experienced high rates of xylazine-fentanyl overdose deaths. Vulnerable populations in Connecticut for special consideration for future intervention and local resource allocation are recommended.
Increasing presence of xylazine in heroin and/or fentanyl deaths, Philadelphia, Pennsylvania, 2010–2019

Jewell Johnson,Lia Pizzicato,Caroline Johnson,Kendra Viner

DOI: https://doi.org/10.1136/injuryprev-2020-043968

IF: 3.7

2021-02-03

Injury Prevention

Abstract:Reports from active drug users state that xylazine, the veterinary tranquilliser, has been increasing in the illicit drug supply in Philadelphia. To describe trends and characteristics of unintentional deaths from heroin and/or fentanyl overdose with xylazine detections occurring in Philadelphia, Pennsylvania, the Philadelphia Department of Public Health analysed data on deaths from unintentional heroin and/or fentanyl overdose from the Philadelphia Medical Examiner’s Office over a 10-year period (2010–2019). Xylazine went from being detected in less than 2% cases of fatal heroin and/or fentanyl overdose between 2010 and 2015 to 262 (31%) of the 858 fatal heroin and/or fentanyl overdose cases in 2019. Currently, information is limited on the presence of xylazine in continental United States. Xylazine’s association with adverse outcomes in other locations indicates that potential health consequences should also be monitored in the USA. Whenever possible, jurisdictions should consistently test for xylazine.

public, environmental & occupational health
National Institute on Drug Abuse Clinical Trials Network Meeting Report: Managing Patients Exposed to Xylazine-Adulterated Opioids in Emergency, Hospital and Addiction Care Settings

Jeanmarie Perrone,Rachel Haroz,Joseph D'Orazio,Giacomo Gianotti,Jennifer Love,Matthew Salzman,Margaret Lowenstein,Ashish Thakrar,Stephanie Klipp,Lisa Rae,Megan K Reed,Edward Sisco,Rachel Wightman,Lewis S Nelson

DOI: https://doi.org/10.1016/j.annemergmed.2024.01.041

Abstract:Used as a veterinary sedative and not approved for human use, xylazine has been increasingly linked with opioid overdose deaths in the United States. A growing number of people have been exposed to xylazine in the illicit opioid supply (especially fentanyl) or in other drugs, particularly in some areas of the Northeast. Xylazine is an α-2 adrenergic agonist that decreases sympathetic nervous system activity. When combined with fentanyl or heroin, it is purported to extend the duration of the opioid's sedative effect and to cause dependence and an associated withdrawal syndrome; however, data to support these concerns are limited. Despite the escalating frequency of detection of xylazine in people with nonfatal and fatal opioid overdose, direct links to these outcomes have not been identified. Because the strongest causal link is to fentanyl coexposure, ventilatory support and naloxone remain the cornerstones of overdose management. Xylazine is also associated with severe tissue injury, including skin ulcers and tissue loss, but little is known about the underlying mechanisms. Nonetheless, strategies for prevention and treatment are emerging. The significance and clinical effects of xylazine as an adulterant is focused on 4 domains that merit further evaluation: fentanyl-xylazine overdose, xylazine dependence and withdrawal, xylazine-associated dermal manifestations, and xylazine surveillance and detection in clinical and nonclinical settings. This report reflects the Proceedings of the National Institute on Drug Abuse Center for the Clinical Trials Network convening of clinical and scientific experts, federal staff, and other stakeholders to describe emerging best practices for treating people exposed to xylazine-adulterated opioids. Participants identified scientific gaps and opportunities for research to inform clinical practice in emergency departments, hospitals, and addiction medicine settings.
Xylazine poisoning: a systematic review

Noah S. Ball,Brittany M. Knable,Taylor A. Relich,Allyson N. Smathers,Michael R. Gionfriddo,Branden D. Nemecek,Courtney A. Montepara,Anthony J. Guarascio,Jordan R. Covvey,David E. Zimmerman

DOI: https://doi.org/10.1080/15563650.2022.2063135

2022-04-20

Clinical Toxicology

Abstract:Xylazine is an alpha-2-adrenergic agonist used for its sedative and analgesic properties in veterinary medicine. While not approved by the Food and Drug Administration for use in humans, anecdotal evidence suggests that exposures in humans is on the rise. We sought to systematically review and synthesize the evidence on xylazine exposure in humans focusing on the clinical presentation, management, and outcomes.We conducted a systematic review of the literature including PubMed, Embase, and Scopus from their inception to September 9, 2021. We searched abstracts from selected emergency medicine and toxicology conferences from 2011 through 2021. We included clinical reports of xylazine exposure in humans. We excluded animal studies, in vitro studies, laboratory studies, or articles in a language other than English. From each included article, we extracted subjective and objective data that focused on clinical presentation, management, and outcomes of patients exposed to xylazine.We evaluated a total of 1409 records, rendering a final set of 17 articles and 2 abstracts meeting inclusion criteria. We identified a total of 98 patients amongst reports ranging from 1979 to 2020 and across nine countries. The most common types of xylazine exposures reported were unintentional exposure and intentional misuse/abuse. Common symptoms on presentation included hypotension, bradycardia, drowsiness, lethargy, while apnea with intubation and death were less frequently reported.Human exposure to xylazine appears to be a rising concern within the prehospital and emergency medicine setting. Although a standardized treatment algorithm cannot be recommended at this time, further research is needed to improve the care of patients exposed to xylazine.

toxicology
Xylazine in the Opioid Epidemic: A Systematic Review of Case Reports and Clinical Implications

Shahana Ayub,Shanli Parnia,Karuna Poddar,Anil K Bachu,Amanda Sullivan,Ali M Khan,Saeed Ahmed,Lakshit Jain

DOI: https://doi.org/10.7759/cureus.36864

2023-03-29

Cureus

Abstract:INTRODUCTION AND OBJECTIVES: The opioid overdose epidemic is exacerbated by the emergence of Xylazine as an illicit drug adulterant. Xylazine, a veterinary sedative, can potentiate opioid effects while also causing toxic and potentially fatal side effects. This systematic review aims to assess the impact of Xylazine use and overdoses within the opioid epidemic context.METHOD: A systematic search was conducted following PRISMA guidelines to identify relevant case reports, and case series related to Xylazine use. A comprehensive literature search included databases like Web of Science, PubMed, Embase, and Google Scholar, utilizing keywords and Medical Subject Headings (MeSH) terms related to Xylazine. Thirty-four articles met the inclusion criteria for this review.RESULTS: Intravenous (IV) administration was a common route for Xylazine use among various methods, including subcutaneous (SC), intramuscular (IM), and inhalation, with overall doses ranging from 40 mg to 4300 mg. The average dose in fatal cases was 1,200 mg, compared to 525 mg in non-fatal cases. Concurrent administration of other drugs, primarily opioids, occurred in 28 cases (47.5%). Intoxication was identified as a notable concern in 32 out of 34 studies, and treatments varied, with the majority experiencing positive outcomes. Withdrawal symptoms were documented in one case study, but the low number of cases with withdrawal symptoms may be attributed to factors such as a limited number of cases or individual variation. Naloxone was administered in eight cases (13.6%), and all patients recovered, although it should not be misconstrued as an antidote for Xylazine intoxication. Of the 59 cases, 21 (35.6%) resulted in fatal outcomes, with 17 involving Xylazine use in conjunction with other drugs. The IV route was a common factor in six out of the 21 fatal cases (28.6%).CONCLUSION: This review highlights the clinical challenges associated with Xylazine use and its co-administration with other substances, particularly opioids. Intoxication was identified as a major concern, and treatments varied across the studies, including supportive care, naloxone, and other medications. Further research is needed to explore the epidemiology and clinical implications of Xylazine use. Understanding the motivations and circumstances leading to Xylazine use, as well as its effects on users, is essential for developing effective psychosocial support and treatment interventions to address this public health crisis.
Xylazine update: Prevalence, treatment and research

Alison Knopf

DOI: https://doi.org/10.1002/adaw.33976

2023-12-15

Alcoholism & Drug Abuse Weekly

Abstract:The federal Centers for Disease Control and Prevention (CDC), which has taken the federal lead on xylazine – the animal tranquilizer that has invaded the illicit fentanyl supply, making a drastic overdose situation even worse – has recently come out with a page on What You Should Know About Xylazine ( https://www.cdc.gov/drugoverdose/deaths/other‐drugs/xylazine/faq.html ).
Xylazine Adulteration of the Heroin-Fentanyl Drug Supply : A Narrative Review

Joseph D'Orazio,Lewis Nelson,Jeanmarie Perrone,Rachel Wightman,Rachel Haroz

DOI: https://doi.org/10.7326/M23-2001

Abstract:Xylazine is an animal sedative, approved by the U.S. Food and Drug Administration, that is commonly used in veterinary medicine and is not approved for human use. Since 2016, xylazine has consistently appeared in the illicitly manufactured fentanyl supply and has significantly increased in prevalence, likely due to its low cost, easy availability, and presumed synergistic psychoactive effect. Clinical experience along with the available pertinent research were used to review xylazine adulteration of the drug supply and provide guidance on the care of patients exposed to xylazine. This review discusses xylazine pharmacology, animal and human clinical effects, and what is known to date about care of patients experiencing acute overdose, xylazine-fentanyl withdrawal, and xylazine-associated wounds.
Overdoses with Xylazine and Fentanyl Recorded in Pennsylvania's Overdose Information Network

Manuel Cano,David Zhu,Yesenia Aponte-Melendez,Pedro Mateu-Gelabert,Alex S. Bennett

DOI: https://doi.org/10.1101/2024.08.29.24312792

2024-09-03

Abstract:Background: This descriptive study examined suspected xylazine co-involvement in law enforcement-recorded fentanyl overdoses in Pennsylvania (excluding Philadelphia), focusing on other drug involvement, naloxone administration, and survival. Methods: We examined data from 10,626 suspected fentanyl-involved overdoses (95 reportedly co-involving xylazine) recorded in the Pennsylvania Overdose Information Network (ODIN), January 2018-July 2024. All measures were based on law enforcement/first-responder assessment/report. We used relative frequencies, Fisher's exact tests, and binomial logistic regression models, comparing overdoses reportedly involving xylazine and fentanyl versus those involving fentanyl but no xylazine. Results: Several drugs were reported in significantly larger proportions of overdoses in the fentanyl-xylazine group than the fentanyl-no-xylazine group: carfentanil (11.6% vs. 2.2%); other synthetic opioids (20.0% vs. 7.6%); methamphetamine (21.1% vs. 6.9%); and benzodiazepines (6.3% vs. 2.3%). Naloxone was administered in 41.1% of the cases reportedly involving xylazine, vs. 67.5% of the no-xylazine cases; 62.1% of the overdoses with xylazine recorded were fatal, compared to 27.7% of the fentanyl-no-xylazine overdoses. In multivariable regression models (among the suspected fentanyl overdoses recorded in ODIN, adjusting for age, gender, race/ethnicity, year, county, and other drugs reported): suspected xylazine involvement was associated with 65% lower odds of naloxone administration (Adjusted Odds Ratio [AOR] 0.35; 95% Confidence Interval [CI], 0.23-0.56) and 79% lower odds of survival (AOR 0.21; 95% CI, 0.13-0.35). Conclusions: In this study of law enforcement-recorded fentanyl overdose events in Pennsylvania, excluding Philadelphia: relative to fentanyl-no-xylazine overdoses, higher proportions of xylazine-fentanyl overdoses co-involved other synthetic opioids or methamphetamine, did not receive naloxone at the scene, and were fatal.
Xylazine effects on opioid-induced brain hypoxia

Shinbe Choi,Matthew R. Irwin,Eugene A. Kiyatkin

DOI: https://doi.org/10.1007/s00213-023-06390-y

2023-06-22

Psychopharmacology

Abstract:Xylazine has emerged in recent years as an adulterant in an increasing number of opioid-positive overdose deaths in the United States. Although its exact role in opioid-induced overdose deaths is largely unknown, xylazine is known to depress vital functions and cause hypotension, bradycardia, hypothermia, and respiratory depression.

pharmacology & pharmacy,neurosciences,psychiatry
The New Stealth Drug on the Street: A Narrative Review of Xylazine as a Street Drug

Joseph Pergolizzi Jr,Jo Ann K LeQuang,Peter Magnusson,Thomas L Miller,Frank Breve,Giustino Varrassi

DOI: https://doi.org/10.7759/cureus.40983

2023-06-26

Cureus

Abstract:Xylazine is an alpha-adrenergic receptor agonist approved for use only in animals with a prescription from a veterinarian. It is a powerful sedative that is slowly infiltrating the recreational street drug scene and is often used by polysubstance abusers. Known as "tranq," it can be fatal, and xylazine-induced toxicity cannot be reversed with naloxone or nalmefene. Due to its vasoconstrictive effects, chronic use of xylazine is associated with necrotic skin lesions and general deterioration of health. Since xylazine is not approved for human use and is not scheduled as a controlled substance, there are no human studies to provide evidence of drug-drug interactions, lethal doses, or reversal protocols. Xylazine is available online without a prescription. Street drug users may take xylazine knowingly or unknowingly, as it is often combined with other illicit substances such as fentanyl. There are no rapid tests for xylazine, although there are specialty tests that can be ordered. Xylazine represents a major threat to street drug users and another challenge to emergency healthcare workers, first responders, and others who care for those who have taken this "new" street drug.
"Tranq-dope": The first fatal intoxication due to xylazine-adulterated heroin in Italy

Annagiulia Di Trana,Alessandro Di Giorgi,Jeremy Carlier,Francesco Serra,Francesco Paolo Busardò,Simona Pichini

DOI: https://doi.org/10.1016/j.cca.2024.119826

2024-07-15

Abstract:Background and aims: The number of xylazine-involved overdose deaths tremendously increased from 2019 onwards in the US. This is due to the "tranq-dope" trend consisting in mixing opioids with the sedative to reduce drug manufacturing costs and enhance their effects. In this study, we report the first fatality involving xylazine-adulterated heroin in the EU. Materials and methods: The subject was a 33-year-old Caucasian male with a documented history of drug abuse who was found dead in a public area with puncture marks at the elbow. Peripheral blood and urine were collected at the autopsy and analyzed by liquid chromatography-high-resolution tandem mass spectrometry (LC-HRMS/MS) after protein precipitation. Results: 6-Monoacetylmorphine, total/free morphine, and codeine blood concentrations of 20.3, 236/105, and 38.3 ng/mL, respectively, indicated recent heroin consumption. Methadone blood concentration was below 10 ng/mL. Alprazolam, nordiazepam, and flurazepam blood concentrations were 23.9, 61.4, and 55.0 ng/mL, respectively. Benzoylecgonine blood concentration was below 5 ng/mL. Xylazine blood and urine concentrations were 105 and 72.6 ng/mL, respectively. Conclusion: The combination of central nervous system depressants, i.e., opioids, benzodiazepines, and xylazine, was the principal cause of death by cardiorespiratory failure. The case was promptly reported to the UE Early Warning System on drugs.
Xylazine awareness and attitudes among people who use drugs in Ohio, 2023-2024

Nichole L Michaels,Saroj Bista,Ashley Short Mejia,Hannah Hays,Gary A Smith

DOI: https://doi.org/10.1186/s12954-024-01097-5

2024-10-14

Abstract:Background: The prevalence of xylazine, a non-opioid tranquilizer not for human consumption, in illicitly manufactured fentanyl is increasing in the United States. However, little is known about xylazine awareness and attitudes among people who use drugs. Methods: A cross-sectional survey of people who use drugs in Ohio was conducted from November 2023 - May 2024 to identify xylazine awareness and attitudes in rural and urban counties across the state. Study participants were recruited from naloxone distribution sites, including health departments, syringe service programs, and community-based organizations. Results: Among 630 people who use drugs in Ohio, more than one-half (53.5%) were unaware of xylazine being in "street drugs," regardless of urbanicity. Among individuals who were aware of xylazine, most (73.0%) indicated they did not want to use the drug and try to avoid it. In addition, 75.8% of this group felt it was "very" or "extremely" important to know if xylazine was in their drugs. Discussion: This research found that many people who use drugs in Ohio are unaware of xylazine and its risks. An important finding of this study is that most individuals who had heard of xylazine did not want to use it and were concerned about knowing whether xylazine was in their drugs.

Xylazine in Overdose Deaths and Forensic Drug Reports in US States, 2019-2022

Drug Overdose Deaths Involving Xylazine, United States, 2018–2021

Public health impact and harm reduction implications of xylazine-involved overdoses: a narrative review

Xylazine Spreads Across the US: A Growing Component of the Increasingly Synthetic and Polysubstance Overdose Crisis

Xylazine in the Unregulated Drug Market: An Integrative Review of Its Prevalence, Health Impacts, and Detection and Intervention Challenges in the United States

Xylazine Abuse, The Growing Risk: A Review of Its Effects, Upsurge Use and Associated Fatalities in the USA and Puerto Rico.

Opioid overdoses involving xylazine in emergency department patients: a multicenter study

Illicitly Manufactured Fentanyl–Involved Overdose Deaths with Detected Xylazine — United States, January 2019–June 2022

Analytical methods for the determination of xylazine in pharmaceutical, clinical and forensic matrices – A review

Modeling Changes of Fatal Xylazine-Involved Drug Overdoses in Connecticut Across Time

Increasing presence of xylazine in heroin and/or fentanyl deaths, Philadelphia, Pennsylvania, 2010–2019

National Institute on Drug Abuse Clinical Trials Network Meeting Report: Managing Patients Exposed to Xylazine-Adulterated Opioids in Emergency, Hospital and Addiction Care Settings

Xylazine poisoning: a systematic review

Xylazine in the Opioid Epidemic: A Systematic Review of Case Reports and Clinical Implications

Xylazine update: Prevalence, treatment and research

Xylazine Adulteration of the Heroin-Fentanyl Drug Supply : A Narrative Review

Overdoses with Xylazine and Fentanyl Recorded in Pennsylvania's Overdose Information Network

Xylazine effects on opioid-induced brain hypoxia

The New Stealth Drug on the Street: A Narrative Review of Xylazine as a Street Drug

"Tranq-dope": The first fatal intoxication due to xylazine-adulterated heroin in Italy

Xylazine awareness and attitudes among people who use drugs in Ohio, 2023-2024